SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SomaLogic, Inc.

SomaLogic is fostering the discovery of effective and safer treatments for patients while empowering more accurate diagnosis, prevention, and treatment of disease through the next generation of proteomics.

SoftBank Capital

T. Rowe Price

Illumina

ARK Investment Management

Corvex

Counterpoint Global

Farallon Capital Management

Perceptive Advisors

Casdin Capital

Janus Henderson Investors

Ziff Capital Partners

Revelation Partners

Amgen

Boston Millennia Partners

Novartis

Redmile Group

Intermountain Ventures

Logos Capital

Millennium Management

SomaLogic

ICYMI ... Andra Krauze, MD, Physician Early Investigator and radiation oncologist at National Cancer Institute (NCI), presented how to effectively balance genomics, transcriptomics, and metabolomics, alongside proteomic platforms and clinical data, along with approaches for connecting proteomic data with the clinic. 

"Harnessing AI and proteomics for glioblastoma"

Catch up on the research here ➡️  https://lnkd.in/gnG4k5ex

#glioblastoma #biomarkerdiscovery #biomarkers 

How are academic, industry and government partners driving the precision neuroscience revolution, both as individual contributors and within the Global Neurodegeneration Proteomics Consortium?  

Now available! Chris Whelan, PhD, Carlos Cruchaga, PhD, and Keenan Walker, PhD, discuss their work measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.  
 
Access the on-demand webinar ➡️ https://bit.ly/3SdOT8r  
 
#Alzheimers # neuroscience #proteomics #biomarkers 

Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on using the NASH bundle of SomaSignal® Tests in a recently completed trial.

🎥 Watch today: Correlation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes

#proteomics #biomarkers #drugdiscovery 

Catching up on research this week? Watch Ali Javaheri, MD, present findings from proteomics-based studies that identified ApoM as a mediator of risk in diabetes, heart failure, and chemotherapeutic cardiotoxicity, as well as the association between ApoM and heart failure outcomes, which has been validated in multiple cohorts using the SomaScan® Assay.

#proteomics #biomarkers #drugdiscovery 

Thank you to all the authors who have published discoveries they’ve made using the SomaScan® Assay. Each new study advances precision medicine worldwide – and inspires us to keep innovating.  
 
📖 Look through all their peer-reviewed research here: https://bit.ly/3RnkGSh 

Narrow your search by keyword. Or filter by date, and catch up on what’s new. 
 
#proteomics #biomarkers #drugdiscovery #drugdevelopment #aptamers 

	Dec '19	Dec '20	Dec '21	Dec '22
net income	-57.00M -	-53.02M 6.99%	-87.55M 65.14%	-109.16M 24.68%
depreciation and amortization	3.16M -	2.82M 10.58%	2.57M 9.00%	4.57M 77.93%
deferred income tax	-8.20M -	13.08M 259.57%	11.61M 11.30%	-806K 106.95%
stock based compensation	13.07M -	15.17M 16.12%	28.41M 87.29%	43.61M 53.47%
change in working capital	-4.87M -	-8.67M 78.08%	5.68M 165.56%	28.01M 392.94%
accounts receivables	84K -	-13.31M 15,940.48%	383K 102.88%	-9.37M 2,545.43%
inventory	-4.95M -	483K 109.76%	-2.96M 712.22%	-3.73M 26.21%
accounts payables		4.03M -	6.46M 60.50%	2.34M 63.78%
other working capital		131K -	1.80M 1,270.99%	38.77M 2,058.52%
other non cash items	3.31M -	2.27M 31.52%	2.30M 1.68%	-66.89M 3,003.43%
net cash provided by operating activities	-50.54M -	-28.34M 43.93%	-36.97M 30.47%	-100.67M 172.28%
investments in property plant and equipment	-680K -	-1.16M 70.15%	-6.73M 481.59%	-5.21M 22.50%
acquisitions net				-13.26M -
purchases of investments		-45.70M -	-279.92M 512.49%	-186.69M 33.31%
sales maturities of investments		37.27M -	101.21M 171.53%	287.70M 184.27%
other investing activites	31.34M -	51K 99.84%	10K 80.39%
net cash used for investing activites	30.66M -	-9.54M 131.09%	-185.43M 1,844.74%	82.54M 144.51%
debt repayment			-36.51M -
common stock issued			357.20M -	5.18M 98.55%
common stock repurchased
dividends paid
other financing activites	144K -	188.77M 130,987.50%	176.81M 6.34%
net cash used provided by financing activities	144K -	188.77M 130,987.50%	497.49M 163.55%	5.18M 98.96%
effect of forex changes on cash	-17K -	-9K 47.06%	-14K 55.56%	-43K 207.14%
net change in cash	-19.74M -	150.88M 864.20%	275.07M 82.31%	-12.98M 104.72%
cash at beginning of period	34.05M -	14.31M 57.98%	165.19M 1,054.40%	440.27M 166.52%
cash at end of period	14.31M -	165.19M 1,054.40%	440.27M 166.52%	427.28M 2.95%
operating cash flow	-50.54M -	-28.34M 43.93%	-36.97M 30.47%	-100.67M 172.28%
capital expenditure	-680K -	-1.16M 70.15%	-6.73M 481.59%	-5.21M 22.50%
free cash flow	-51.22M -	-29.50M 42.41%	-43.70M 48.16%	-105.88M 142.29%

COM:SOMALOGIC

SomaLogic Inc

Last Close

2.29

05/01 21:00

Market Cap

396.23M

Beta: -

Volume Today

33.91M

Avg: -

Preview